Loading
Life sciences · Journal article
International Journal of Biology and Life Sciences · October 8, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Triple-negative breast cancer (TNBC), characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) expression, has long been associated with limited treatment targets, a high risk of recurrence and metastasis, and a poor prognosis. In recent years, antibody-drug conjugates (ADCs), which link targeted antibodies to cytotoxic payloads, have provided a new avenue for breakthroughs in precision therapy for TNBC. TROP2 is highly expressed in various epithelial tumors and is associated with tumor invasion, metastasis, and poor prognosis; it has thus become a key target for TNBC-ADC drug development. Existing studies indicate that TROP2-ADCs, represented by Sacituzumab Govitecan (SG), can improve treatment outcomes for patients with advanced TNBC; however, challenges remain, including unclear mechanisms of resistance, a lack of biomarkers, difficulties in managing adverse reactions, and insufficient evidence for specific patient populations. Future efforts should focus on further optimizing ADC structures, refining TROP2 detection standards, and exploring personalized combination therapy strategies to advance the development of precision medicine for TNBC. This article provides a review of the fundamental mechanisms, clinical research progress, challenges in clinical application, and future directions for TROP2-ADC drugs in the treatment of TNBC.